Overview

Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease

Status:
Not yet recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

A Phase 2a study in men and women with early Alzheimer's disease to evaluate the pharmacodynamics, pharmacokinetics and safety of obicetrapib therapy.

Phase:

Phase 2

Details

Lead Sponsor:

NewAmsterdam Pharma